FACACLASSIC

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”

HHS - 960 - National Cancer Advisory Board - Statutory (Congress Created)

GENERAL INFORMATION

Committee Name	National Cancer Advisory Board	Agency Name	Department of Health and Human Services
Fiscal Year	2025	Committee Number	960
Original Establishment Date	11/20/1985	Committee Status	Chartered
Actual Termination Date		Committee URL	http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm
Actual Merged Date		Presidential Appointments*	Yes
New Committee This FY	No	Max Number of Members*	30
Terminated This FY	No	Designated Fed Officer Position Title*	DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Merged This FY		Designated Federal Officer Prefix
Current Charter Date	5/31/2024	Designated Federal Officer First Name*	PAULETTE
Date Of Renewal Charter	5/31/2026	Designated Federal Officer Middle Name	S.
Projected Termination Date		Designated Federal Officer Last Name*	GRAY
Exempt From Renewal*	No	Designated Federal Officer Suffix	PH.D.
Specific Termination Authority		Designated Federal Officer Phone*	240-276-6340
Establishment Authority*	Statutory (Congress Created)	Designated Federal Officer Fax*	240-276-7815
Specific Establishment Authority*	42 U.S.C. 284a	Designated Federal Officer Email*	grayp@mail.nih.gov
Effective Date Of Authority*	11/20/1985
Exempt From EO 13875 Discretionary Cmte	Not Applicable
Committee Type*	Continuing
Presidential*	No
Committee Function*	Other Committee

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*	Continue
Legislation to Terminate Required	Not Applicable
Legislation Status	Not Applicable
How does cmte accomplish its purpose?*	The National Cancer Advisory Board (NCAB), composed of both scientific and public members, provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed $50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). In FY 2024, the NCAB reviewed 14,437 NCI applications requesting $5,669,050,029 and 3 FDA SBIR applications requesting $287,455. During the year, the NCAB was presented reports on various topics related to cancer research in general. Board discussions and reports included a wide variety of topics including CDK4/6 Activity During the Cell Cycle by Live-Cell Imaging; Integrative Population-Based Characterization of Mosaic Chromosomal Alterations Uncovering Etiologic Insights for Hematologic Malignancies; Complexity of Genomic Aberrations in Human Breast Cancer for Precision Oncology; NCI Center for Cancer Genomics; NCI Virtual Clinical Trials Office Pilot Program; NCI's Support of Early Career Cancer Investigators; NCI’s Childhood Cancer Data Initiative (CCDI); Artificial Intelligence (AI); the NCI Community Oncology Research Program (NCORP); and the National Clinical Trials Network (NCTN). NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Experimental Therapeutics and Population Sciences, Epidemiology, and Disparities. They also provided insights regarding reports from the NCAB Subcommittees on Planning and Budget; Cancer Centers; and Clinical Investigations. At the Joint Meeting of the National Advisory Council on Alcohol Abuse and Alcoholism, National Advisory Council on Drug Abuse and NCAB met to hear reports regarding the Healthy Brain and Child Development (HBCD) Study; Adolescent Brain and Cognitive Development (ABCD) Study; the START Program and Advancing the Prediction of Adolescent Alcohol Use Onset by Deriving PolyeXposure Alcohol Risk Scores using the ABCD Study; Racial Inequities and Neuroimaging Findings in ABCD; and updates from the NCI, NIAAA, and NIDA regarding efforts associated with the Collaborative Research on Addiction at NIH (CRAN) initiative. Lastly, NCAB meeting minutes for the following meetings, i.e., the September 2023 virtual meeting, November 2023 Joint NCI Board of Scientific Advisors/NCAB virtual meeting, February 2024 virtual meeting, NIAAA/NIDA/NCAB May 2024 hybrid meeting, and June 2024 Joint NCI BSA/NCAB in-person/hybrid meeting were approved by the Board members during fiscal year 2024.
How is membership balanced?*	The Board will consist of not more than 18 members appointed by the President (appointed members) and 12 nonvoting ex officio members. The nonvoting ex officio members will include the Secretary; the Director of the Office of Science and Technology Policy; the Director, NIH; the Under Secretary for Health of the Department of Veterans Affairs; the Director of the National Institute for Occupational Safety and Health; the Director of the National Institute of Environmental Health Sciences; the Secretary of Labor; the Commissioner of the Food and Drug Administration; the Administrator of the Environmental Protection Agency; the Chairman of the Consumer Product Safety Commission; the Assistant Secretary of Defense for Health Affairs; and the Director of the Office of Energy Research of the Department of Energy (or their designees). All appointed members must be eligible to serve as Special Government Employees (SGEs) and will serve as SGEs. Two-thirds of the appointed members will be selected from among the leading representatives of the health and scientific disciplines (including not less than 2 individuals who are leaders in the fields of public health and the behavioral or social sciences) relevant to the activities of NCI. One-third of the appointed members will be representatives from the general public, including leaders in fields of public policy, law, health policy, economics and management. Not less than five of the appointed members will be individuals knowledgeable in environmental carcinogenesis (including carcinogenesis involving occupational and dietary factors). Not less than one member shall be an individual knowledgeable in pediatric oncology.
How frequent & relevant are cmte mtgs?*	As mandated, meetings are held not less than four times a year. The committee met five times during this reporting period. The Board met jointly with NIAAA/NIDA on 8 May 2024 hybrid and jointly with the NCI Board of Scientific Advisors for the November 2023 virtual and June 2024 in-person/hybrid meetings. The Board also met virtually at the February 2024 and in-person/hybrid at the September 2024 meetings. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing scientific programs. The Ad Hoc Subcommittee on Experimental Therapeutics and the Subcommittee on Cancer Centers met on 29 November 2023. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities, the Ad Hoc Subcommittee on Experimental Therapeutics, and the Subcommittee on Planning and Budget met on 8 February 2024. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities, the Ad Hoc Subcommittee on Experimental Therapeutics, and the Subcommittee on Clinical Investigations met on 11 June 2024. The Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities, and the Ad Hoc Subcommittee on Experimental Therapeutics met on 3 September 2024.
Why advice can't be obtained elsewhere?*	The NCAB provides second level of peer review and advises on policy development; program implementation, and evaluation; and identifies research needs and opportunities of the Institute. The quality, scope, and balance of advice from this Board cannot be obtained from NIH staff or from other established sources as membership of the Board is constituted to meet specific requirements of the mandated mission of the Board and of the NCI.
Why close or partially close meetings?	The meetings of the NCAB were partially closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussion of applications could reveal confidential trade secrets or commercial property such as patentable material and personal information, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Recommendation Remarks	Committee Function: Other - National Scientific and Advisory. Max Number of Members Total: The Charter allows the Committee to have 30 authorized members included but not limited to 18 SGEs and 12 Ex-Officio Members. There are 8 Alternates to Ex-Officio Members (Drs. Joseph R. Graber, John Gordon, Michelle Heacock, Michael Kelley, Mathew Memoli, Richard Pazdur, Craig Shriver, and Kerry Souza), which is a total of 26 members, four less than the Max number of members. Members Rotating Off/On-Boarding: no member rotated-off and five members were on-boarded (Drs. Callisia Clarke, Karen Emmons, Ediah Nduom, Kimberly Stegmaier and Mrs. Tamika Felder). This is why the Charter states 18 potential members, and this ACR lists 18 current members. Members: Dr. Luis Diaz was terminated. As such, his term of service end date is different than what was reported on the FY24 ACR. Ex Officio Members: Dr. Joseph Graber has resigned. As such, his term of service end date is different than what was reported on the FY24 ACR. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute. Reports: The NCAB did not produce a report this fiscal year.

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*	Yes	Action Reorganize Priorities*	Yes
Outcome Trust In Government	No	Action Reallocate Resources	Yes
Outcome Major Policy Changes	Yes	Action Issued New Regulations	No
Outcome Advance In Scientific Research	Yes	Action Proposed Legislation	No
Outcome Effective Grant Making	Yes	Action Approved Grants Or Other Payments	Yes
Outcome Improved Service Delivery	No	Action Other	Yes
Outcome Increased Customer Satisfaction	No	Action Comment	An action of approved or recommended for grants receiving review by this Board does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by the National Advisory Council that includes program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps, have been completed, NIH officials make funding decisions on individual grant applications. NCI used its resources to support the best science and ensure continued advances with a focus on the eight goals of the National Cancer Plan which include the following: preventing cancer; detecting cancer early; developing effective treatments; eliminating inequities; delivering optimal care; engaging every person; maximizing data utility; and optimizing the workforce. There were also well-reasoned discussions regarding CDK4/6 Activity During the Cell Cycle by Live-Cell Imaging; Integrative Population-Based Characterization of Mosaic Chromosomal Alterations Uncovering Etiologic Insights for Hematologic Malignancies; Complexity of Genomic Aberrations in Human Breast Cancer for Precision Oncology; NCI Center for Cancer Genomics; NCI Virtual Clinical Trials Office Pilot Program; NCI's Support of Early Career Cancer Investigators; NCI’s Childhood Cancer Data Initiative (CCDI); Artificial Intelligence (AI); the NCI Community Oncology Research Program (NCORP); and the National Clinical Trials Network (NCTN). NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Experimental Therapeutics and Population Sciences, Epidemiology, and Disparities.
Outcome Implement Laws/Reg Requirements	Yes	Grants Review*	Yes
Outcome Other	Yes	Number Of Grants Reviewed	14,440
Outcome Comment	The NCAB continues to be instrumental in monitoring the development and execution of the activities of the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. In 2024, NCI used its resources to support the best science and ensure continued advances with a focus on the eight goals of the National Cancer Plan which include the following: preventing cancer; detecting cancer early; developing effective treatments; eliminating inequities; delivering optimal care; engaging every person; maximizing data utility; and optimizing the workforce. There were also well-reasoned discussions regarding CDK4/6 Activity During the Cell Cycle by Live-Cell Imaging; Integrative Population-Based Characterization of Mosaic Chromosomal Alterations Uncovering Etiologic Insights for Hematologic Malignancies; Complexity of Genomic Aberrations in Human Breast Cancer for Precision Oncology; NCI Center for Cancer Genomics; NCI Virtual Clinical Trials Office Pilot Program; NCI's Support of Early Career Cancer Investigators; NCI’s Childhood Cancer Data Initiative (CCDI); Artificial Intelligence (AI); the NCI Community Oncology Research Program (NCORP); and the National Clinical Trials Network (NCTN). NCAB members provided insights regarding reports from the NCAB Ad Hoc Subcommittees on Experimental Therapeutics and Population Sciences, Epidemiology, and Disparities. Additionally, the Board deliberated and accepted the revised mission statement of the Ad Hoc Subcommittee on Experimental Therapeutics and approved the establishment of a Board of Scientific Advisors Ad Hoc Working Group in Support of Efforts to Enhance Community Cancer Research and Quality Care.	Number Of Grants Recommended	14,440
Cost Savings*	Unable to Determine	Dollar Value Of Grants Recommended	$5,669,337,484.00
Cost Savings Comment	NIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.	Grants Review Comment	The number of grants reviewed/recommended and dollar value includes NCI grants and FDA SBIR grants.
Number Of Recommendations*	282	Access Contact Designated Fed. Officer*	Yes
Number Of Recommendations Comment	In addition to some general recommendations, in FY 2024, some specific committee recommendations included the following: A motion to accept the report of the 29 November 2023 NCAB ad hoc Subcommittee on Experimental Therapeutics meeting was approved unanimously. A motion to accept the report of the 29 November 2023 NCAB Subcommittee on Cancer Centers meeting was approved unanimously. A motion to approve the NCI Annual Delegations of Authority was approved unanimously. A motion to accept the report of the 8 February 2024 NCAB ad hoc Subcommittee on Population Science, Epidemiology, and Disparities meeting was approved unanimously. A motion to accept the report of the 8 February 2024 NCAB ad hoc Subcommittee on Experimental Therapeutics meeting was approved unanimously. A motion to accept the report of the 8 February 2024 NCAB Subcommittee on Budget and Planning meeting was approved unanimously. A motion to concur on establishing a BSA ad hoc Working Group in Support of Efforts to Enhance Community Cancer Research and Quality Care was approved unanimously. A motion to accept the report of the 11 June 2024 NCAB Clinical Investigations Subcommittee meeting was approved unanimously. A motion to accept the report of the 11 June 2024 NCAB ad hoc Population Science, Epidemiology, and Disparities Subcommittee meeting was approved unanimously. A motion to accept the report of the 11 June 2024 NCAB ad hoc Experimental Therapeutics Subcommittee meeting was approved unanimously. A motion to accept the revised mission statement of the NCAB ad hoc Experimental Therapeutics Subcommittee was approved unanimously. A motion to accept the report of the 3 September 2024 NCAB ad hoc Subcommittee on Population Science, Epidemiology, and Disparities meeting was approved unanimously. A motion to accept the report of the 3 September 2024 NCAB ad hoc Subcommittee on Experimental Therapeutics meeting was approved unanimously.	Access Agency Website	Yes
% of Recs Fully Implemented*	0.00%	Access Committee Website	Yes
% of Recs Fully Implemented Comment	Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.	Access GSA FACA Website	Yes
% of Recs Partially Implemented*	0.00%	Access Publications	Yes
% of Recs Partially Implemented Comment	Information on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.	Access Other	Yes
Agency Feedback*	Yes	Access Comment	Information on the NCAB can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint Presentations and reports is located here. Additionally, the public may view the NCAB meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback Comment*	Information is provided to the public at the open session of each Board meeting through reports and the Director’s update. The public can view information related to the Board through the NCAB’s official website.	Narrative Description*	NIH's mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce illness and disability. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients. NCI works to fulfill that mission with the support of the National Cancer Advisory Board (NCAB), which is composed of both scientific and public members, and provides second level peer review, makes recommendations for support of grants, contract proposals, and cooperative agreements, where direct costs per annum exceed $50,000; advises on policy development, program implementation and evaluation; and identifies research needs of the National Cancer Institute (NCI). During the year, the NCAB was presented reports on various topics related to cancer research in general, and the operational aspects of the Institute's intramural and extramural programs. The NCAB provides advice on a continuing basis on the type of scientific research programs that should be supported and on how best to carry out the designated mission and responsibilities of the NCI. In addition, this Board provides ongoing review of the relevance and effectiveness of the existing research programs.

COSTS

1. Payments to Non-Federal Members*		1. Est Paymnts to Non-Fed Membrs Nxt FY*
2. Payments to Federal Members*		2. Est. Payments to Fed Members Next FY*
3. Payments to Federal Staff*		3. Estimated Payments to Federal Staff*
4. Payments to Consultants*		4. Est. Payments to Consultants Next FY*
5. Travel Reimb. For Non-Federal Membrs*		5. Est Travel Reimb Non-Fed Membr nxtFY*
6. Travel Reimb. For Federal Members*		6. Est Travel Reimb For Fed Members*
7. Travel Reimb. For Federal Staff*		7. Est. Travel Reimb to Fed Staf Nxt FY*
8. Travel Reimb. For Consultants*		8. Est Travel Reimb to Consltnts Nxt FY*
10. Other Costs		10. Est. Other Costs Next FY*
11. Total Costs	$0.00	11. Est. Total Next FY*	$0.00
Date Cost Last Modified	3/14/2025 9:24 AM	Est. Fed Staff Support Next FY*
Federal Staff Support (FTE)*		Est Cost Remarks
Cost Remarks

Interest Areas

Category Area Environment Environmental Issues Health Health Care Medicine Health and Health Research

Custom Links

Committee Level Reports